BTIG raises PennyMac Financial target to $135, maintains Buy rating
BTIG analyst Eric Hagen adjusted the price target for PennyMac Financial Services, Inc. (NYSE:PFSI), increasing it to $135 from the previous $115 while reaffirming a Buy rating on the stock. The stock is currently trading near its 52-week high of $119.
Boot Barn price target raised to $200 from $190 at BTIG
BTIG raised the firm’s price target on Boot Barn (BOOT) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q3 results were
Intuitive Surgical price target raised to $622 from $561 at BTIG
BTIG raised the firm’s price target on Intuitive Surgical (ISRG) to $622 from $561 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s System sales and procedure growth Y/Y meaningfully exceeded the Street’s high expectations by 58 units and 170bps respectively,
PulteGroup price target lowered to $145 from $156 at BTIG
BTIG lowered the firm’s price target on PulteGroup (PHM) to $145 from $156 and keeps a Buy rating on the shares. The company’s EPS beat was
Dynatrace price target raised to $67 from $63 at BTIG
BTIG raised the firm’s price target on Dynatrace (DT) to $67 from $63 and keeps a Buy rating on the shares. The company posted decent Q3
Evolent Health price target lowered to $20 from $29 at BTIG
BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher medical trend and their ability to capture a net EBITDA benefit of $60M in 2025 after accounting for about $100M-$105M in EBITDA benefit from higher rates and some conversion to Tech Enabled Services for some clients,
BTIG cuts PulteGroup stock price target to $145 from $156
BTIG analyst Carl Reichardt Jr. revised the price target on PulteGroup (NYSE:PHM) stock to $145.00, down from the previous $156.00, while maintaining a Buy rating on the shares. The adjustment follows PulteGroup's fourth-quarter earnings report,
BTIG Research Estimates D.R. Horton’s Q4 Earnings (NYSE:DHI)
Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...
Semiconductor selloff was in the charts, says BTIG's Krinsky
What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...
Business Wire4d
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the ...
Nasdaq1mon
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...
Deckers Outdoor remains defensive, CFO warns of FX headwinds
Deckers Outdoor stock falls 14% as raised guidance falls short of expectations, facing headwinds from strong dollar and ...
BTIG maintains Neutral on NVR stock, trims EPS estimates
BTIG analyst Carl Reichardt Jr. maintained a Neutral rating on shares of NVR Inc . (NYSE:NVR), while slightly lowering ...
medtechdive5d
Doctors expect Boston Scientific to lead PFA race, survey finds
Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...
Tech’s drawdown could create a new leadership potential – BTIG’s Krinsky
Market technician Jonathan Krinsky analyzes the shift in market leadership from technology to healthcare amid recent ...